MK 8800Alternative Names: P04945; SCH900800
Latest Information Update: 07 Jan 2014
At a glance
- Originator Merck & Co
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 07 Jan 2014 No development reported - Preclinical for Parkinson's disease in USA (PO)
- 22 Dec 2011 Preclinical trials in Parkinson's disease in USA (PO)